Reviewer’s report

Title: Short versus standard treatment with Pegylated interferon alfa-2a plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the CLEO trial.

Version: 2 Date: 11 December 2009

Reviewer: Piero Almasio

Reviewer’s report:

1. In the abstract the dose of Ribavirin is 800-1,200 mg/day, but in the method section the Authors indicate that the dose was 1,000-1,200 according to body weight. Please solve this discrepancy.

2. The legend of table 2 is misleading: the correct definition should be “PATIENTS CHARACTERISTICS ACCORDING TO ACHIEVEMENT OF RAPID VIROLOGICAL RESPONSE”

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: Yes, and I have assessed the statistics in my report.